Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company

Metageno­mi, a genet­ic med­i­cines com­pa­ny with a ver­sa­tile port­fo­lio of whol­ly owned, next-gen­er­a­tion gene edit­ing sys­tems, has been named as one of Fast Company’s 16th Annu­al World’s Most Inno­v­a­tive Com­pa­nies. Metageno­mi is lead­ing a new wave of genet­ic med­i­cines com­pa­nies work­ing to trans­late pow­er­ful next-gen­er­a­tion gene edit­ing sys­tems into ther­a­pies, with the goal of cor­rect­ing the under­ly­ing dis­ease-caus­ing gene. Metageno­mi has dis­cov­ered more than 20,000 edit­ing sys­tems and uses high-through­put genome screen­ing, AI-based cloud com­put­ing, and pro­tein engi­neer­ing to cre­ate opti­mized gene edit­ing tools matched to spe­cif­ic dis­ease targets.

It is an hon­or to be rec­og­nized as one of the most inno­v­a­tive com­pa­nies by Fast Com­pa­ny for our work in devel­op­ing the largest library of next-gen­er­a­tion gene edit­ing sys­tems that fuel our pipeline of nov­el genet­ic med­i­cines,” said Bri­an C. Thomas, Metageno­mi Founder and CEO. We set out to be a dis­rup­tor in the gene edit­ing space, lever­ag­ing our mas­sive data­base of genomes from uncul­ti­vat­ed organ­isms to build gene edit­ing tools beyond the stan­dard, first gen­er­a­tion CRISPR-cas9 enzyme. Our sys­tems are high­ly effi­cient, pre­cise, and can broad­ly tar­get any codon in the human genome. What dri­ves us is the cura­tive poten­tial that gene edit­ing ther­a­pies bring. Gene edit­ing is a rev­o­lu­tion that will allow us to address a wide range of dis­eases affect­ing mil­lions of patients world­wide who today have few treat­ment options.”

Fast Company’s World’s Most Inno­v­a­tive Com­pa­nies list rec­og­nizes pro­found prod­ucts, ser­vices and ini­tia­tives poised to have trans­for­ma­tive impact. The list and cov­er­age span dozens of indus­tries, themes, and regions, and stands as the defin­ing record of the future of business.

In oth­er recog­ni­tions of its impact in the life sci­ences indus­try, Metageno­mi was named to the 2022 End­points 11, which rec­og­nizes the top pri­vate biotech­nol­o­gy com­pa­nies that are push­ing the enve­lope in drug devel­op­ment. Fur­ther­more, Jian Irish, Pres­i­dent and Chief Oper­at­ing Offi­cer of Metageno­mi, was named by End­points News as one of its 2022 Women in Bio­phar­ma, a list of extra­or­di­nary women engaged in drug research and devel­op­ment worldwide.

About Metageno­mi

Metageno­mi is a gene edit­ing com­pa­ny com­mit­ted to devel­op­ing poten­tial­ly cura­tive ther­a­peu­tics by lever­ag­ing a pro­pri­etary tool­box of next-gen­er­a­tion gene edit­ing sys­tems to accu­rate­ly edit DNA where cur­rent tech­nolo­gies can­not. Our metage­nomics-pow­ered dis­cov­ery plat­form and ana­lyt­i­cal exper­tise reveal nov­el cel­lu­lar machin­ery sourced from oth­er­wise unknown organ­isms. We adapt and forge these nat­u­ral­ly evolved sys­tems into pow­er­ful gene edit­ing sys­tems that are ultra small, extreme­ly effi­cient, high­ly spe­cif­ic and have a decreased risk of immune response. These sys­tems fuel our pipeline of nov­el med­i­cines. Our goal is to rev­o­lu­tion­ize gene edit­ing for the ben­e­fit of patients around the world. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.